Company: Movetis
Financing: $63.5M

Belgium-based Movetis was founded in 2006 after the company acquired a portfolio of gastrointestinal candidates from Johnson & Johnson subsidiaries Janssen and Ortho-McNeil. In January, the company landed a €49 million ($63.5M) first round led by Sofinnova Partners and Life Sciences Partners. Sofinnova Ventures, KBC, GIMV, Quest for Growth and BIP Investment Partners also participated.

The company’s lead candidate is RESOLOR, which is in Phase III development for the treatment of severe chronic constipation and is expected to his the market by 2009. A second compound, M0002, is in Phase IIa development for treatment of ascites. Movetis has two other clinical-stage candidates: one for pediatric reflux and a second for diabetic gastroparesis.



Suggested Articles

Karen DeSalvo's appointment is the latest in a string of hires that deepen the tech giant’s investment in and focus on healthcare.

Spring Bank’s hepatitis B drug, given in tandem with Gilead’s Vemlidy, tamped down on chronic disease in 23% of patients in a phase 2 study.

Verseau will use the money to start testing its macrophage checkpoint modulators in humans.